OPTIMA
Optimal treatment for patients with solid tumors in Europe through Artificial Intelligence
RIA (Research and Innovation Action)
Funded by the Innovative Medicines Initiative (IMI) 2 Project
01/10/2021 – 30/09/2026 (5 years)
Stichting European Urological Foundation
VIEW PARTNERS >
Stichting European Urological Foundation, Netherlands
Lunds Universitet, Sweden
Erasmus Universitair Medisch Centrum Rotterdam, Netherlands
Association EISBM, France
The University Court of The University Of Aberdeen, United Kingdom
Tartu Ulikool, Estonia
Universita Vitasalute San Raffaele, Italy
Queen Mary University of London, United Kingdom
Helmholtzzentrum Dresdenrossendorf EV, Germany
Helios Klinikum Emil Von Behring GMBH, Germany
Uppsala Universitet, Sweden
The Chancellor, Masters And Scholars Of The University Of Oxford, United Kingdom
Universitat Wien, Austria
Istituto Europeo Di Oncologia SRL, Italy
Ludwigmaximiliansuniversitaet Muenchen, Germany
University College London, United Kingdom
European Organisation for Research and Treatment of Cancer AISBL, Belgium
Institut de Cancerologie De L’Ouest, France
Universiteit Maastricht, Netherlands
Fundacio Institut Universitari Pera La Recerca A L’atencio Primaria De Salut Jordi Gol I Gurina, Spain
European Respiratory Society, Switzerland
Deutsche Krebsgesellschaft EV, Germany
European Lung Foundation, United Kingdom
European Lung Foundation Europe, Belgium
European Cancer Patient Coalition, Belgium
TTOPSTART BV, Netherlands
GMV Soluciones Globales Internet SAU, Spain
Information Technology For Translational Medicine (ITTM) SA, Luxembourg
Smart Reporting GMBH, Germany
OWKIN France, France
Arttic Innovation GMBH, Germany
YDEAL.NET Software LDA, Portugal
Pfizer Limited, United Kingdom
Bayer Aktiengesellschaft, Germany
AMGEN, Belgium
F. Hoffmann-La Roche AG, Switzerland
ABBVIE INC, United States
Why it matters
Following the experience with the predecessor (PIONEER) project, OPTIMA intends to extend its goals to other two cancers, breast and lung cancer. Taking PIONEER as a template and starting point, the idea of this project is to improve the integration of all the information available from patients, translate it into a standardised format, and process it through Artificial Intelligence to achieve the best ways for early diagnosis, personalised therapy.
What ECPC does
ECPC is contributing to the overall project by providing a voice to prostate , breast and lung cancer patients through offering expert patient input and advice during the entire life cycle of the project. The participation of ECPC ensures that the patients engage in their disease management, thus leading to better treatment adherence and improved Quality of Life (QoL). This includes and is not limited to reviewing informed consent forms, surveys, study protocols and guidelines, setting up patient focus groups, drafting patient information leaflets and brochures, and the successful communication and dissemination of the project’s deliverables. ECPC is also working to ensure that the visual identity of PIONEER is aligned with the branding of the DO-IT communication and support action for all BD4BO projects supported by the IMI.
This project has received funding from the European Union’s Horizon 2020 research and innovation
programme under grant agreement No 101034347